Rhelion Subsidiary Filament to Speak at FDA Psychedelic Hearing Today

Rhelion Life Sciences' subsidiary Filament Health will deliver oral comments at the FDA public hearing on the potential future therapeutic use of psychedelic drugs. President Sarit Hashkes will provide remarks, focusing on the development, evaluation, and potential therapeutic use of psychedelic drugs. Filament's patented psilocybin drug candidate, PEX010, is a pharmaceutical-grade psychedelic drug produced using proprietary extraction, purification, and stabilization methods. The FDA hearing aims to gather input on the regulated access pathway for psychedelic medicines in the United States.